VolitionRx Earns 2 CE Marks for Colorectal Cancer Tests

VolitionRx has received CE marking for its two NuQ blood assays — NuQ T003 and NuQ V001 — for the detection of colorectal cancer, the Belgium-based company announced Thursday.

In a 430-patient trial, the tests identified 86 percent of early-stage colorectal cancers at 78 percent specificity and 86 percent of colorectal adenomas at high risk of becoming cancerous.

The tests require one drop of blood to identify and screen nucleosomes for epigenetic cancer markers, which include changes to DNA and variations to histone proteins.

Last September, the company received CE marking for its assay NuQ X001S for the same indication. — Anisa Jibrell